Allogeneic versus autologous stem-cell therapy: A comparison of manufacturing costs and commercialization challenges

BioPharm International

Volumn 25, Issue 7, 2012, Pages 36-40

  Malik, Nafees N ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL RENEWAL; CELL TYPE; CLINICAL EFFECTIVENESS; COMMERCIAL PHENOMENA; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; QUALITY CONTROL; SAFETY; SCREENING;

EID: 84864754295     PISSN: 1542166X     EISSN: 19391862     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (8)

1. M. Körbling and Z. Estrov, N. Engl. J. Med. 349 (6), 570-582 (2003).
2. D. Srivastava and K.N. Ivey, Nature 441 (7097), 1097-1099 (2006).
3. C. Aguayo-Mazzucato and S. Bonner-Weir, Nat. Rev. Endocrinol. 6 (3), 139-148 (2010).
4. O. Lindvall and Z. Kokaia, J. Clin. Invest. 120 (1), 29-40 (2010).
5. R. McKernan, J. McNeish and D. Smith, Cell Stem-Cell 6 (6), 517-520 (2010).
6. C. Mason, Regen. Med. 2 (1), 11-18 (2007).
7. L. Jackson, D.R. Jones, P. Scotting and V. Sottile, J. Postgrad. Med. 53 (2), 121-127 (2007).
8. E. Fossett and W.S. Khan, Stem-Cells Int'l., Article ID 465259, 2012. doi:10.1155/2012/465259.